Questioning the Methodologic Superiority of ‘Placebo’ Over ‘Active’ Controlled Trials

  title={Questioning the Methodologic Superiority of ‘Placebo’ Over ‘Active’ Controlled Trials},
  author={Jeremy Howick},
  journal={The American Journal of Bioethics},
  pages={34 - 48}
  • J. Howick
  • Published 25 August 2009
  • Psychology, Medicine
  • The American Journal of Bioethics
A resilient issue in research ethics is whether and when a placebo-controlled trial (PCT) is justified if it deprives research subjects of a recognized treatment. The clinicians' moral duty to provide the best available care seems to require the use of ‘active’ controlled trials (ACTs) that use an established treatment as a control whenever such a therapy is available. In another regard, ACTs are supposedly methodologically inferior to PCTs. Hence, the moral duty of the clinical researcher to… 

Ethical Issues in the Difference Between Placebo-Controlled and Active-Controlled Trials

  • C. Petrini
  • Psychology
    The American journal of bioethics : AJOB
  • 2009
The ethical implications of Howick’s theory regarding a few aspects of informed consent and equipoise are considered, including whether active-controlled trials (ACTs) are methodologically inferior to placebocontrolled trials (PCTs), are considered.

Conflating Scientific With Clinical Considerations

The ethical premises that create Howick’s (2009) dilemma are flawed and it is argued previously that it is better to refrain from using phrases like “the best available treatment” (Van der Graaf, Van Delden 2009, 37).

Assay Sensitivity and the Epistemic Contexts of Clinical Trials

The legitimate worries behind assay sensitivity can be better understood as the need for researchers to articulate their experimental heuristics and to demonstrate a robust pattern of evidence across a series of trials.

Questioning the Methodological Superiority of ‘Placebo’ over ‘Active’ Controlled Trials

  • M. Enkin
  • Medicine
    The American journal of bioethics : AJOB
  • 2009
The new paradigm of evidence-based medicine revived and re-honored the much maligned placebo, this time not to praise it as a source of consolation in the clinic, but to condemn it asA source of bias to be controlled for in the testing situation, a bias that could affect physician and patient alike.

Giving and taking: ethical treatment assignment in controlled trials

It is asserted that patients being invited to participate in controlled trials cannot, ethically, be expected to forego proven beneficial forms of care.

Empirical evidence against placebo controls

The evidence presented in this paper suggests that the Declaration of Helsinki be reconsidered, and perhaps revised, in light of actual practice, and what clinical investigators believe to be ethically acceptable.

Are explanatory trials ethical? Shifting the burden of justification in clinical trial design

It is argued that while explanatory trials often have some social value, many have less social value than their pragmatic counterparts, and a preliminary defense of the position that clinical researchers should aim to conduct pragmatic trials is provided.

Placebo orthodoxy and the double standard of care in multinational clinical research

This majority view found in medical research is that placebo-controlled trials are methodologically superior to comparative trials that use active controls, and it is argued that lives were unnecessarily lost in these trials as a result.

Placebo—To be or not to be? Are there really alternatives to placebo-controlled trials?

The relativity of ‘placebos’: defending a modified version of Grünbaum’s definition

It is shown that with four modifications, Grünbaum’s definition provides a defensible account of placebos for the purpose of constructing placebo controls within clinical trials.



What Makes Placebo-Controlled Trials Unethical?

This work argues that clinical equipoise provides erroneous ethical guidance in the case of placebo-controlled trials, because it ignores the ethically relevant distinction between clinical trials and treatment in the context of clinical medicine and the methodological limitations of active- controlled trials.

The ethics and science of placebo-controlled trials: assay sensitivity and the Duhem-Quine thesis.

It is concluded that the assay sensitivity argument fails to demonstrate that placebo- controlled trials are preferable, methodologically or otherwise, to active-controlled trials.

The Ethics of Placebo-controlled Trials: A Comparison of Inert and Active Placebo Controls

The analysis provides explicit justification for the apparent caution of Institutional Review Boards or ethics committees when reviewing sham operations, especially when the expected harm is not trivial and the risk of exploitation is high.

Placebo-Controlled Trials and Active-Control Trials in the Evaluation of New Treatments. Part 1: Ethical and Scientific Issues

It is concluded that placebo-controlled trials may be ethically conducted even when effective therapy exists, as long as patients will not be harmed by participation and are fully informed about their alternatives.

Placebo-Controlled Trials and Active-Control Trials in the Evaluation of New Treatments. Part 2: Practical Issues and Specific Cases

It is concluded that placebo controls are ethical when delaying or omitting available treatment has no permanent adverse consequences for the patient and as long as patients are fully informed about their alternatives.

The double-blind, randomized, placebo-controlled trial: gold standard or golden calf?

  • T. Kaptchuk
  • Philosophy
    Journal of clinical epidemiology
  • 2001

What makes clinical research ethical?

7 requirements are proposed that systematically elucidate a coherent framework for evaluating the ethics of clinical research studies and are universal, although they must be adapted to the health, economic, cultural, and technological conditions in which clinical research is conducted.

The continuing unethical conduct of underpowered clinical trials.

It is concluded that underpowered trials are ethical in only 2 situations: small trials of interventions for rare diseases in which investigators document explicit plans for including their results with those of similar trials in a prospective meta-analysis, and early-phase trials in the development of drugs or devices, provided they are adequately powered for defined purposes other than randomized treatment comparisons.

What are the main methodological problems in the estimation of placebo effects?